世界の非動物代替試験市場2021年-2030年:技術別(細胞培養技術、ハイスループット技術、分子画像、オミック技術)、方法別(細胞アッセイ、生化学的アッセイ、インシリコ、エクスビボ)、エンドユーザー別(製薬産業、化粧品・家庭用品、診断、化学産業、食品産業)、地域別

【英語タイトル】Non-animal Alternative Testing Market by Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, and Omic Technology), Method (Cellular Assay, Biochemical Assay, In Silico, and Ex-vivo), End-user (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemical Industry, and Food Industry), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2030

Research Diveが出版した調査資料(RDV22MA017)・商品コード:RDV22MA017
・発行会社(調査会社):Research Dive
・発行日:2022年2月
・ページ数:290
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD5,700 ⇒換算¥843,600見積依頼/購入/質問フォーム
5 UserUSD8,700 ⇒換算¥1,287,600見積依頼/購入/質問フォーム
Enterprise UserUSD10,700 ⇒換算¥1,583,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Research Dive社の本調査レポートは、世界の非動物代替試験市場を調査対象とし、調査手法、エグゼクティブサマリー、市場概要、新型コロナウイルス感染症の影響分析、技術別(細胞培養技術、ハイスループット技術、分子画像、オミック技術)分析、方法別(細胞アッセイ、生化学的アッセイ、インシリコ、エクスビボ)分析、エンドユーザー別(製薬産業、化粧品・家庭用品、診断、化学産業、食品産業)分析、地域別分析、企業情報など、以下の構成でまとめております。
・調査手法
・エグゼクティブサマリー
・市場概要
・新型コロナウイルス感染症の影響分析
・世界の非動物代替試験市場規模:技術別(細胞培養技術、ハイスループット技術、分子画像、オミック技術)
・世界の非動物代替試験市場規模:方法別(細胞アッセイ、生化学的アッセイ、インシリコ、エクスビボ)
・世界の非動物代替試験市場規模:エンドユーザー別(製薬産業、化粧品・家庭用品、診断、化学産業、食品産業)
・世界の非動物代替試験市場規模:地域別
・企業情報

According to Research Dive analysis, the global non-animal alternative market was valued at $9,080.10 million in 2020 and is projected to reach $ 29,390.20 million by 2030, registering a CAGR of 13.0%.

COVID-19 Impact on the Non-animal Alternative Testing Market:
The non-animal alternative testing market share experienced a major growth in the corona virus pandemic. Due to high prevalence of corona virus infection rate, worldwide, and increased occurrence of deadly symptoms among the patients, the demand for a high potential drug has increased. Owing to such situations, researchers have increasingly used alternative to animal testing methods to develop vaccines against the virus as these tests give fast results. Such factors are likely to boost the market growth of the non-animal alternative testing market in the pandemic time period.

Non-animal Alternative Testing Market Analysis:
Rising prevalence of diseases such as viral infections among people, worldwide, is expected to drive the non-animal alternative testing market size growth in the coming years. Also, rising animal testing ban on different product categories such as cosmetics and food is further anticipated to boost non-animal alternative testing market size growth in the coming years.
However, lack of knowledge about the working of non-animal alternative testing software and devices is likely to impede the non-animal alternative testing market growth in the next few years.
Many drugs and cosmetic manufacturing companies have got a golden opportunity to step into non-animal alternative testing market and develop their product portfolios in non-animal alternative testing software and technologies. This is due to patient’s preference for no animal testing products and services. Such factors are likely to boost the non-animal alternative testing market share growth in the forecast time period.
Based on technology, the global non-animal alternative market is segmented into cell culture technology, high throughput technology, molecular imaging, and omic technology. Omic technology market sub-segment is anticipated to have the fastest market growth and the market shall generate a revenue of $ 2483.70 million in 2030.
Based on method, the global non-animal alternative market is segmented into cellular assay, biochemical assay, in silico, and ex-vivo. The cellular assay sub-segment is predicted to have the highest revenue in the global market and register a revenue of $12,369.50 million during the forecast period.

Based on end-use, the global non-animal alternative market is segmented into pharmaceutical industry, cosmetics & household products, diagnostics, chemical industry, and food industry. Pharmaceutical industry sub-segment is predicted to have the highest market share in the global market and register a revenue of $13,993.80 million during the forecast period.

Based on geographical scope, the market was investigated across North America, Europe, Asia-Pacific, and LAMEA. The Asia-Pacific non-animal alternative testing market is expected to observe the fastest growth and register a revenue of $4,761.20 million in the predicted time span.
The companies involved in the non-animal alternative testing market are Vitrocell Systems GMBH, Evotec, Biovit, MB Research Laboratory, Emulate, Inc., Tara Biosystems, Bio- Rad, Abbott Laboratories, Hurel Corporation, and Tissues GmbH.

❖ レポートの目次 ❖

CHAPTER 1:INTRODUCTION

1.1.Research methodology

1.1.1.Desk research
1.1.2.Real-time insights and validation
1.1.3.Forecast model
1.1.4.Assumptions & forecast parameters

1.1.4.1.Assumptions
1.1.4.2.Forecast parameters

CHAPTER 2:EXECUTIVE SUMMARY

2.1.360° summary
2.2.Technology trends
2.3.Method trends
2.4.End user trends

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key takeaways

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.2.2.1.Top winning strategies, by year
3.2.2.2.Top winning strategies, by development
3.2.2.3.Top winning strategies, by company
3.3.Porter’s five forces analysis

3.4.Market dynamics
3.5.Drivers

3.5.1.Government initiatives to promote non-animal alternative testing to drive the market
3.5.2.Increased research and development activities in scientific field to boost the market growth

3.6.Restraints

3.6.1.Persistent use of animal test subjects in various research fields to restrain the market growth

3.7.Opportunities

3.7.1.Increasing advancements in research and development techniques to flourish the market growth

3.8.Technology landscape
3.9.Regulatory landscape
3.10.Patent landscape
3.11.Market value chain analysis
3.12.Strategic overview

CHAPTER 4:IMPACT OF COVID-19 ON GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET

4.1.Introduction
4.2.COVID-19 health assessment
4.3.Impact of COVID-19 on the global economy
4.4.Impact of COVID-19 on global non-animal alternative testing market

4.4.1.Social impact
4.4.2.Technological impact
4.4.3.Investment scenario

4.5.Non-animal alternative testing market size and forecast, by region, 2020-2030

CHAPTER 5:GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY TECHNOLOGY

5.1.Overview

5.1.1.Market size and forecast, by technology

5.2.Cell Culture Technology

5.2.1.Key market trends, growth factors and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market share analysis, by country

5.3.High Throughput Technology

5.3.1.Key market trends, growth factors and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market share analysis, by country

5.4.Molecular Imaging

5.4.1.Key market trends, growth factors and opportunities
5.4.2.Market size and forecast, by region
5.4.3.Market share analysis, by country

5.5.Omic technology

5.5.1.Key market trends, growth factors and opportunities
5.5.2.Market size and forecast, by region
5.5.3.Market share analysis, by country

CHAPTER 6:GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY METHOD6.1.Overview

6.1.1.Market size and forecast, by method

6.2.Cellular assay

6.2.1.Key market trends, growth factors and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market share analysis, by country

6.3.Biochemical assay

6.3.1.Key market trends, growth factors and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market share analysis, by country

6.4.In-silico

6.4.1.Key market trends, growth factors and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market share analysis, by country

6.5.Ex-vivo

6.5.1.Key market trends, growth factors and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market share analysis, by country

CHAPTER 7:GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET BY END-USER

7.1.Overview

7.1.1.Market size and forecast, by end user

7.2.Pharmaceutical Industry

7.2.1.Key market trends, growth factors and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market share analysis, by country

7.3.Cosmetic industry and household products

7.3.1.Key market trends, growth factors and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market share analysis, by country

7.4.Diagnostics

7.4.1.Key market trends, growth factors and opportunities
7.4.2.Market size and forecast, by region
7.4.3.Market share analysis, by country

7.5.Chemical Industry

7.5.1.Key market trends, growth factors and opportunities
7.5.2.Market size and forecast, by region
7.5.3.Market share analysis, by country

7.6.Food Industry

7.6.1.Key market trends, growth factors and opportunities
7.6.2.Market size and forecast, by region
7.6.3.Market share analysis, by country

CHAPTER 8:GLOBAL NON-ANIMAL ALTERNATIVE TESTING MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast, by region

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.Market size and forecast, by technology
8.2.3.Market size and forecast, by method
8.2.4.Market size and forecast, by end user
8.2.5.Market size and forecast, by country

8.2.6.U.S.

8.2.6.1.Market size and forecast, by technology
8.2.6.2.Market size and forecast, by method
8.2.6.3.Market size and forecast, by end user

8.2.7.Canada

8.2.7.1.Market size and forecast, by technology
8.2.7.2.Market size and forecast, by method
8.2.7.3.Market size and forecast, by end user

8.2.8.Mexico

8.2.8.1.Market size and forecast, by technology
8.2.8.2.Market size and forecast, by method
8.2.8.3.Market size and forecast, by end user

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Market size and forecast, by technology
8.3.3.Market size and forecast, by method
8.3.4.Market size and forecast, by end user
8.3.5.Market size and forecast, by country

8.3.6.Germany

8.3.6.1.Market size and forecast, by technology
8.3.6.2.Market size and forecast, by method
8.3.6.3.Market size and forecast, by end user

8.3.7.UK

8.3.7.1.Market size and forecast, by technology
8.3.7.2.Market size and forecast, by method
8.3.7.3.Market size and forecast, by end user

8.3.8.France

8.3.8.1.Market size and forecast, by technology
8.3.8.2.Market size and forecast, by method
8.3.8.3.Market size and forecast, by end user

8.3.9.Spain

8.3.9.1.Market size and forecast, by technology
8.3.9.2.Market size and forecast, by method
8.3.9.3.Market size and forecast, by end user

8.3.10.Italy

8.3.10.1.Market size and forecast, by technology
8.3.10.2.Market size and forecast, by method
8.3.10.3.Market size and forecast, by end user

8.3.11.Rest of Europe

8.3.11.1.Market size and forecast, by technology
8.3.11.2.Market size and forecast, by method
8.3.11.3.Market size and forecast, by end user

8.4.Asia-Pacific

8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Market size and forecast, by technology
8.4.3.Market size and forecast, by method
8.4.4.Market size and forecast, by end user
8.4.5.Market size and forecast, by country

8.4.6.China

8.4.6.1.Market size and forecast, by technology
8.4.6.2.Market size and forecast, by method
8.4.6.3.Market size and forecast, by end user

8.4.7.Japan

8.4.7.1.Market size and forecast, by technology
8.4.7.2.Market size and forecast, by method
8.4.7.3.Market size and forecast, by end user

8.4.8.India

8.4.8.1.Market size and forecast, by technology
8.4.8.2.Market size and forecast, by method
8.4.8.3.Market size and forecast, by end user

8.4.9.South Korea

8.4.9.1.Market size and forecast, by technology
8.4.9.2.Market size and forecast, by method
8.4.9.3.Market size and forecast, by end user

8.4.10.Australia

8.4.10.1.Market size and forecast, by technology
8.4.10.2.Market size and forecast, by method
8.4.10.3.Market size and forecast, by end user

8.4.11.Rest of Asia-Pacific

8.4.11.1.Market size and forecast, by technology
8.4.11.2.Market size and forecast, by method
8.4.11.3.Market size and forecast, by end user

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.2.Market size and forecast, by technology
8.5.3.Market size and forecast, by method
8.5.4.Market size and forecast, by end user
8.5.5.Market size and forecast, by country

8.5.6.Latin America

8.5.6.1.Market size and forecast, by technology
8.5.6.2.Market size and forecast, by method
8.5.6.3.Market size and forecast, by end user

8.5.7.Middle East

8.5.7.1.Market size and forecast, by technology
8.5.7.2.Market size and forecast, by method
8.5.7.3.Market size and forecast, by end user

8.5.8.Africa

8.5.8.1.Market size and forecast, by technology
8.5.8.2.-Market size and forecast, by method
8.5.8.3.Market size and forecast, by end user

CHAPTER 9:COMPANY PROFILES

9.1.VITROCELL SYSTEMS GMBH

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Product portfolio
9.1.4.Key strategic moves and developments

9.2.Evotec (Cryptoex Plc)

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Product portfolio
9.2.4.Key strategic moves and developments

9.3.BIOIVT

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Product portfolio

9.4.MB Research Laboratories

9.4.1.Company overview
9.4.2.Product portfolio
9.4.3.Key strategy moves and development

9.5.Emulate, Inc.

9.5.1.Company overview
9.5.2.Product portfolio
9.5.3.Key strategy moves and development

9.6.TARA Biosystems

9.6.1.Company overview
9.6.2.Operating business segments
9.6.3.Product portfolio
9.6.4.Key strategy moves and development

9.7.Bio-Rad Laboratories, Inc.

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Research and Development Expenditure
9.7.6.Business performance
9.7.7.Key strategic moves and developments

9.8.HμREL CORPORATION

9.8.1.Company overview
9.8.2.Product portfolio
9.8.3.Key strategy moves and development

9.9.Abbott Laboratories

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and developments

9.10.TissUse GmbH

9.10.1.Company overview
9.10.2.Product portfolio
9.10.3.Key strategy moves and development

PURCHASE OPTIONS
READ ONLY $2999
INDIVIDUAL USER $5700
MULTI USER $8700
BUSINESS USER $10700
ADD TO CART
BUY NOW
PERSONALIZE THIS RESEARCH
Triangulate with your own data
Request your format and definition
Get a deeper dive on a specific application, geography, customer or competitor
10% OFF ON CUSTOMIZATION
Speak To The Analyst
Or Schedule A Call
CONTACT US
+ 1-888-961-4454 Toll – Free
+ 91-788-802-9103 -Int’l
support@researchdive.com



★調査レポート[世界の非動物代替試験市場2021年-2030年:技術別(細胞培養技術、ハイスループット技術、分子画像、オミック技術)、方法別(細胞アッセイ、生化学的アッセイ、インシリコ、エクスビボ)、エンドユーザー別(製薬産業、化粧品・家庭用品、診断、化学産業、食品産業)、地域別] (コード:RDV22MA017)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の非動物代替試験市場2021年-2030年:技術別(細胞培養技術、ハイスループット技術、分子画像、オミック技術)、方法別(細胞アッセイ、生化学的アッセイ、インシリコ、エクスビボ)、エンドユーザー別(製薬産業、化粧品・家庭用品、診断、化学産業、食品産業)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆